The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Market Value Of The Gene Therapy For Inherited Genetic Disorders Market Projected To Expand During 2026–2030?
The market size for gene therapy addressing inherited genetic disorders has seen swift expansion recently. It will grow from $4.05 billion in 2025 to $4.84 billion in 2026 at a compound annual growth rate (CAGR) of 19.3%. This historical growth can be attributed to several factors including the limited availability of advanced gene therapy techniques, a reliance on conventional treatments for genetic disorders, the increasing prevalence of inherited genetic diseases, early clinical research focused on viral vectors, and a rising awareness of rare disease management.
The gene therapy for inherited genetic disorders market is anticipated to experience significant expansion in the coming years. It is projected to reach **$9.69 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 19.0%.** This growth during the forecast period is fueled by the development of innovative viral vectors and gene editing technologies, the broadening scope of RNA-based therapies, increased implementation of ex vivo stem cell therapies, growing investment in personalized gene therapies, and the enhanced capacity of hospitals and specialty clinics for gene therapy administration. Prominent trends expected in the forecast period include the extended use of viral vector-based therapies for rare genetic disorders, an increase in ex vivo gene therapy applications, wider adoption of RNA-based therapeutics, an intensifying focus on addressing neurological and ophthalmic disorders, and the incorporation of personalized medicine into gene therapy.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp
What Key Growth Drivers Are Influencing The Gene Therapy For Inherited Genetic Disorders Market?
The increasing need for personalized medicine is projected to fuel the expansion of the gene therapy for inherited genetic disorders market in the future. Personalized medicine involves customizing medical interventions based on an individual’s unique genetic profile and personal characteristics to achieve optimal care. This approach is gaining traction due to advancements in genetic technologies, making it simpler and more affordable to tailor treatments to an individual’s specific genetic makeup. Personalized medicine enhances gene therapy by adapting treatments to each patient’s distinct genetic profile, thereby ensuring precise gene targeting and delivery, improving effectiveness, and minimizing adverse effects. For example, in February 2024, the US-based non-profit organization, Personalized Medicine Coalition, reported that in 2023, the United States Food and Drug Administration (FDA) sanctioned 16 new personalized treatments for rare disease patients, a significant rise from 6 in 2022. The personalized treatments newly approved in 2023 also encompassed seven cancer drugs and three for other diseases and conditions. As a result, the growing demand for personalized medicine is a primary driver for the growth of the gene therapy for inherited genetic disorders market.
What Segment Categories Are Evaluated In The Gene Therapy For Inherited Genetic Disorders Market Study?
The gene therapy for inherited genetic disorders market covered in this report is segmented –
1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy
2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders
3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors
2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases
3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies
4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy
What Trends Are Affecting The Gene Therapy For Inherited Genetic Disorders Market Dynamics?
Leading companies within the gene therapy for inherited genetic disorders market are concentrating on the development of advanced solutions, such as ex-vivo CRISPR/Cas9-based gene-edited cell therapies, to address the escalating need for one-time, potentially curative treatments. These innovations aim to lessen lifelong reliance on transfusions, frequent hospitalizations, and the high expenditures associated with chronic care for inherited blood and metabolic disorders. Ex-vivo CRISPR/Cas9 gene-edited cell therapy entails collecting a patient’s hematopoietic stem cells, utilizing CRISPR/Cas9 to precisely edit disease-causing genes (or regulatory elements that increase protective fetal hemoglobin), and subsequently reinfusing the modified cells so they can engraft and deliver lasting therapeutic benefits. For example, in December 2023, Vertex Pharmaceuticals, a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval and achieved commercial availability for CASGEVY (exagamglogene autotemcel). This is an ex-vivo, CRISPR/Cas9-based gene-edited cell therapy specifically for sickle cell disease, an inherited genetic disorder. CASGEVY is derived from a patient’s own hematopoietic stem cells, which are gene-edited to elevate fetal hemoglobin. The product’s makeup features autologous stem cells modified with CRISPR/Cas9; its function is to raise durable fetal hemoglobin levels, thereby preventing red-blood-cell sickling. Unique attributes include precise genome editing (CRISPR/Cas9) performed ex vivo and a one-time administration delivering a durable effect. Its primary application is the treatment of severe sickle cell disease (and related indications currently under regulatory evaluation), with trials demonstrating significant reductions in vaso-occlusive crises and transfusion dependence compared to previous standard-of-care.
Which Companies Are Influencing The Gene Therapy For Inherited Genetic Disorders Market?
Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG
Access The Complete Gene Therapy For Inherited Genetic Disorders Market Report:
Which Region Holds The Largest Share In The Gene Therapy For Inherited Genetic Disorders Market?
North America was the largest region in the gene therapy for inherited genetic disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Gene Therapy For Inherited Genetic Disorders Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp
Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2026, By The Business Research Company
Asphalt Mixing Plants Market Report 2026
https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report
Asphalt Pavers Market Report 2026
https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report
Asphalt Additives Market Report 2026
https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model